These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 33235624

  • 1. Efficacy of infliximab in the treatment of Kawasaki disease: A systematic review and meta-analysis.
    Lu Z, Wang F, Lv H.
    Exp Ther Med; 2021 Jan; 21(1):15. PubMed ID: 33235624
    [Abstract] [Full Text] [Related]

  • 2. The effectiveness of infliximab for Kawasaki disease in children: systematic review and meta-analysis.
    Li D, Li X, Dou W, Zheng Y.
    Transl Pediatr; 2021 May; 10(5):1294-1306. PubMed ID: 34189087
    [Abstract] [Full Text] [Related]

  • 3. Comparison of second-line therapy in IVIg-refractory Kawasaki disease: a systematic review.
    Crayne CB, Mitchell C, Beukelman T.
    Pediatr Rheumatol Online J; 2019 Nov 27; 17(1):77. PubMed ID: 31775898
    [Abstract] [Full Text] [Related]

  • 4. Predictors of intravenous immunoglobulin-resistant Kawasaki disease in children: a meta-analysis of 4442 cases.
    Li X, Chen Y, Tang Y, Ding Y, Xu Q, Sun L, Qian W, Qian G, Qin L, Lv H.
    Eur J Pediatr; 2018 Aug 27; 177(8):1279-1292. PubMed ID: 29948255
    [Abstract] [Full Text] [Related]

  • 5. Infliximab versus intravenous immunoglobulin for refractory Kawasaki disease: a phase 3, randomized, open-label, active-controlled, parallel-group, multicenter trial.
    Mori M, Hara T, Kikuchi M, Shimizu H, Miyamoto T, Iwashima S, Oonishi T, Hashimoto K, Kobayashi N, Waki K, Suzuki Y, Otsubo Y, Yamada H, Ishikawa C, Kato T, Fuse S.
    Sci Rep; 2018 Jan 31; 8(1):1994. PubMed ID: 29386515
    [Abstract] [Full Text] [Related]

  • 6. Intravenous Immunoglobulin Gamma (IVIG) versus IVIG Plus Infliximab in Young Children with Kawasaki Disease.
    Han CL, Zhao SL.
    Med Sci Monit; 2018 Oct 11; 24():7264-7270. PubMed ID: 30307902
    [Abstract] [Full Text] [Related]

  • 7. Plasma exchange and infliximab as a third-line therapy for refractory infantile Kawasaki disease.
    Ansai H, Masuda H, Nakao H, Nishimura N, Kubota M.
    Pediatr Int; 2022 Jan 11; 64(1):e15226. PubMed ID: 35831245
    [Abstract] [Full Text] [Related]

  • 8. Coronary Artery Complication in Kawasaki Disease and the Importance of Early Intervention : A Systematic Review and Meta-analysis.
    Chen S, Dong Y, Kiuchi MG, Wang J, Li R, Ling Z, Zhou T, Wang Z, Martinek M, Pürerfellner H, Liu S, Krucoff MW.
    JAMA Pediatr; 2016 Dec 01; 170(12):1156-1163. PubMed ID: 27749951
    [Abstract] [Full Text] [Related]

  • 9. Current knowledge of TNF-α monoclonal antibody infliximab in treating Kawasaki disease: a comprehensive review.
    Chen J, Liao J, Xiang L, Zhang S, Yan Y.
    Front Immunol; 2023 Dec 01; 14():1237670. PubMed ID: 37936712
    [Abstract] [Full Text] [Related]

  • 10. Infliximab as an alternative therapy for refractory adult onset Kawasaki disease: A case report.
    Kawaguchi T, Rikitake Y, Tsuruda T, Kawata C, Rikitake M, Iwao K, Aizawa A, Kariya Y, Matsuda M, Miyauchi S, Umekita K, Takajo I, Okayama A.
    Medicine (Baltimore); 2018 Oct 01; 97(40):e12720. PubMed ID: 30290679
    [Abstract] [Full Text] [Related]

  • 11. Infliximab Plus Intravenous Immunoglobulin (IVIG) Versus IVIG Alone as Initial Therapy in Children With Kawasaki Disease Presenting With Coronary Artery Lesions: Is Dual Therapy More Effective?
    Jone PN, Anderson MS, Mulvahill MJ, Heizer H, Glodé MP, Dominguez SR.
    Pediatr Infect Dis J; 2018 Oct 01; 37(10):976-980. PubMed ID: 29461447
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness analysis of infliximab for the treatment of Kawasaki disease refractory to the initial treatment: A retrospective cohort study.
    Takura T, Horiuchi S.
    J Cardiol; 2022 Aug 01; 80(2):172-178. PubMed ID: 35341683
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 01; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 14. Effective infliximab therapy for the early regression of coronary artery aneurysm in Kawasaki disease.
    Nagatomo Y, Muneuchi J, Nakashima Y, Nanishi E, Shirozu H, Watanabe M, Uike K, Nagata H, Hirata Y, Yamamura K, Takahashi Y, Okada S, Suzuki Y, Hasegawa S, Ohga S.
    Int J Cardiol; 2018 Nov 15; 271():317-321. PubMed ID: 30144998
    [Abstract] [Full Text] [Related]

  • 15. Effect and Safety of TNF Inhibitors in Immunoglobulin-Resistant Kawasaki Disease: a Meta-analysis.
    Xue LJ, Wu R, Du GL, Xu Y, Yuan KY, Feng ZC, Pan YL, Hu GY.
    Clin Rev Allergy Immunol; 2017 Jun 15; 52(3):389-400. PubMed ID: 27550227
    [Abstract] [Full Text] [Related]

  • 16. Infliximab is the new kid on the block in Kawasaki disease: a single-centre study over 8 years from North India.
    Singh S, Sharma D, Suri D, Gupta A, Rawat A, Rohit MK.
    Clin Exp Rheumatol; 2016 Jun 15; 34(3 Suppl 97):S134-8. PubMed ID: 27086575
    [Abstract] [Full Text] [Related]

  • 17. Elevated Serum IL-17A in Kawasaki Disease Patients Predicts Responsiveness to Intravenous Immunoglobulin Therapy.
    Lu Y, Hu FQ.
    Int Arch Allergy Immunol; 2024 Sep 10; ():1-7. PubMed ID: 39255783
    [Abstract] [Full Text] [Related]

  • 18. [Therapeutic effectiveness of intravenous immunoglobulin at 1 g/kg and 2 g/kg on Kawasaki disease: a comparative and follow-up study].
    Qin LJ, Wang HW, Hu XF, Liu QJ, Shi H, Wei YX, Chen QJ, Cheng PX.
    Zhonghua Er Ke Za Zhi; 2006 Dec 10; 44(12):891-5. PubMed ID: 17254453
    [Abstract] [Full Text] [Related]

  • 19. Risk Factors of Intravenous Immunoglobulin Resistance in Children With Kawasaki Disease: A Meta-Analysis of Case-Control Studies.
    Liu G, Wang S, Du Z.
    Front Pediatr; 2020 Dec 10; 8():187. PubMed ID: 32373568
    [Abstract] [Full Text] [Related]

  • 20. Transcriptional regulation by infliximab therapy in Kawasaki disease patients with immunoglobulin resistance.
    Ogihara Y, Ogata S, Nomoto K, Ebato T, Sato K, Kokubo K, Kobayashi H, Ishii M.
    Pediatr Res; 2014 Sep 10; 76(3):287-93. PubMed ID: 24964229
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.